Tackling the remaining challenges of multiple sclerosis

With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest

Novartis ups 2019 guidance after strong Q2

Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis drug Cosentyx being the star performer.

Understanding Multiple Sclerosis

Informative downloadable pack on Multiple Sclerosis

Novartis secures initial block on Gilenya generics in US

Celgene gets MS blockbuster-in-waiting ozanimod back on trac...

Regulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple sclerosis, setting up verdicts next year.

German Merck shows new data backing BTK drug evobrutinib in ...

Germany’s Merck KGaA has announced new mid-stage data that it says support further studies into its BTK inhibitor drug evobrutinib in multiple sclerosis, which could provide patients with a